Fig 1: Significance of cumulative risk score for all the participants based on six biomarkers (P3NP, CAF22, osteonectin, irisin, FABP3 and MIF). Receiver operating characteristic (ROC) curves for all the participants (A), healthy controls (B) and the patients with COPD (C) and CHF (D). The area under the curve (AUC) was calculated for each group to determine the significance of the biomarkers panel in diagnosis of sarcopenia.
Fig 2: Comparison of circulating irisin (A), FABP3 (B) and MIF (C) levels in healthy controls (N = 87) and patients with COPD (N = 86) and CHF (N = 81). The biomarkers levels were generally higher in the participants with advanced sarcopenia based on SPPB (D, E, and F) and SARC-F (G, H, and I) scoring. Values are expressed as mean ± SD, one-way analysis of variance. *p < 0.05.
Fig 3: Cumulative risk score for all the participants based on six biomarkers (P3NP, CAF22, osteonectin, irisin, FABP3 and MIF). The scatter plot of the participants with the median risk score (cutoff value = 3.86) was applied to divide into high- and low-risk groups (A). The relative proportion of the clinically diagnosed sarcopenic patients in the two risk-groups (B) and participants’ categorization based on SARC-F scores (C) in the three study cohorts. The relative proportion of the sarcopenic patients as defined by SARC-F criteria in the two risk-groups (D) in healthy controls and patients with COPD and CHF. *p < 0.05.
Supplier Page from Abcam for Human H-FABP ELISA Kit